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Abstract
Background: No screening programs are available for ovarian or endometrial cancer. One reason for this is the low
incidence of the conditions, resulting in low positive predictive values for tests, which are not very specific. One
way of addressing this problem might be to use risk factors to define subpopulations with a higher incidence. The
aim of this study was to investigate the extent to which a medical history of endometriosis can serve as a risk
factor for ovarian or endometrial cancer.
Methods: In a hospital-based case–control analysis, the cases represented patients with endometrial or ovarian
cancer who were participating in studies aimed at assessing the risk for these diseases. The controls were women
between the age of 40 and 85 who were invited to take part via a newspaper advertisement. A total of 289 cases
and 1016 controls were included. Using logistic regression models, it was tested whether self-reported endometriosis is
a predictor of case–control status in addition to age, body mass index (BMI), number of pregnancies and previous oral
contraceptive (OC) use.
Results: Endometriosis was reported in 2.1 % of the controls (n = 21) and 4.8 % of the cases (n = 14). Endometriosis
was a relevant predictor for case–control status in addition to other predictive factors (OR 2.63; 95 % CI, 1.28 to 5.41).
Conclusion: This case–control study found that self-reported endometriosis may be a risk factor for endometrial
or ovarian cancer in women between 40 and 85 years. There have been very few studies addressing this issue,
and incorporating it into a clinical prediction model would require a more precise characterization of the risk
factor of endometriosis.
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Background
Ovarian cancer is associated with a high mortality rate
in comparison with other cancers. In the United States,
the incidence of ovarian cancer is estimated to be
around 22,200 annually. About 14,000 of these women
are expected to die of the disease [1]. In Germany the
corresponding figures are 7400 and 5500 [2]. This high
mortality rate is mainly the consequence of ineffective
early detection or screening programs. Most of the can-
cers are diagnosed at advanced stages. Uterine endomet-
rial cancer is the most frequent type of gynecological
cancer. In Germany, there are approximately 11,600 new
diagnoses every year and 2400 disease-related deaths [2].
Although the mortality due to endometrial cancer is
fairly low, there are no established early detection
methods or screening programs for this disease. Earlier
detection would result in much less invasive surgery and
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less use of radiotherapy and chemotherapy, leading to
substantial benefits for the patients.
With regard to ovarian cancer, effective risk-reducing strat-
egies have been described. Bilateral salpingo-oophorectomy
has been shown to reduce the risk among BRCA muta-
tion carriers by 71–96 % [3–5]. Numbers of live births,
oral contraceptive use, and tubal ligation are also asso-
ciated with a significant reduction in the lifetime risk of
ovarian cancer.
There are no established screening programs for endo-
metrial cancer, but risk-modifying strategies are known
that allow the risk of endometrial cancer to be con-
trolled — such as weight control, physical activity, and
no exogenous unopposed estrogen [6–9].
Risk factors are therefore of special interest for both
diseases, since accurate risk prediction might make
individualized early detection or screening programs
possible. Risk factors for ovarian cancer include repro-
ductive behavior and use of hormonal therapies. Preg-
nancies and the use of oral contraceptives can reduce
the incidence of ovarian cancer [10]. Mutations in the
BRCA1 and BRCA2 genes are reported to lead to a life-
time risk of about 20–40 and 15–25 %, respectively
[11]. Large-scale genotyping efforts have recently iden-
tified and confirmed a total of 11 low-penetrance risk
loci that are common in the population [12–20].
Endometrial cancer risk factors include hormonal
and metabolic factors such as obesity, tamoxifen use,
diabetes, hypertension, and high dietary fat consump-
tion [21]. With regard to genetic risk factors, endomet-
rial cancer is the most common malignancy in women,
with mutations associated with Lynch syndrome [22].
Genome-wide association studies have identified some
low-penetrance loci, but large-scale confirmation stud-
ies are still pending [23–25].
In this study endometriosis is evaluated as a risk factor
for ovarian- or endometrial cancer. Endometriosis is a
chronic disease that affects 4–30 % of all women during
the reproductive age [26–28]. Furthermore it is one of
the most frequent gynecological diseases. However it
can reasonably be assumed, that the prevalence is about
10 % [28]. The pathogenesis of endometriosis is consid-
ered to be complex. Historically a metaplastic transform-
ation of peritoneal cells or the still favourably retrograde
menstruation of cells through the tubes into the periton-
eal cavity are discussed [29]. On a molecular level differ-
ent pathways such as the estrogen and progesterone
pathway, vasculogenesis, sphingolipids, prostaglandins,
and cytokines appear to be involved.
Pelvic pain during menstruation is the main symp-
tom in patients with endometriosis. Other symptoms
can be chronic lower abdominal pain, dysuria, dysche-
zia and/ or dyspareunia. The disease is characterized
by endometrial cells outside the uterus and is located
mainly in the retrouterine pouch. The diagnosis
occurs in gynecological examination and especially
during laparoscopic surgeries with histological verifi-
cation [30]. Therapy options comprise mainly medica-
tion and surgical therapy. The surgical removal of the
lesion is often the first line therapy [31].
An association between endometriosis and both dis-
eases has been suggested, and in the case of ovarian
cancer the connection is clearly established [32–35].
Patients with endometriosis tend to be younger and to
be diagnosed at earlier stages and with lower-grade
ovarian cancer lesions [36, 37]. With regard to endo-
metrial cancer, the evidence is less clear. A reduced risk
of endometrial cancer was even found in a nested case–
control study including 39 patients with endometrial
cancer and 211 controls (OR 0.58; 95 % CI, 0.42 to
0.81) [37]. In a different nested case–control study, pa-
tients were found to have a relative risk (RR) of 1.23
(95 % CI, 0.63 to 2.38) [38]. However, most of the rele-
vant studies only include a small number of events, so
that definitive conclusions about associations cannot as
yet be drawn [39–42].
The aim of the present case–control study was to inves-
tigate the extent to which a medical history of endometri-
osis represents a risk factor for ovarian or endometrial
cancer in addition to age, body mass index (BMI), number
of pregnancies, and previous oral contraceptive (OC) use.
Methods
A series of case–control and cohort studies have been
conducted in the Department of Gynecology and Ob-
stetrics at Erlangen University Hospital in an effort to
identify risk factors for breast cancer and gynecological
cancer, as well as prognostic factors. These are: 1. The
Bavarian Ovarian Cancer Study (BAV) which was con-
ducted from 2002 to 2011 and was affiliated to large-
scale research consortia working on identifying genetic
and epidemiologic risk factors [13–17, 19, 20], as well as
prognostic factors [43–45]. 2. The Bavarian Endometrial
Cancer Study (BECS) conducted from 2002 to 2013 also
affiliated to larger research consortia [23–25]. 3. The
Bavarian Breast Cancer Cases and Controls Study
(BBCC) [17, 46–51] conducted from 2002 to 2013. The
corresponding controls were recruited using local news-
paper advertisements inviting women over the age of 40
without breast, ovarian or endometrial cancer anam-
nesis, respectively.
Cases of this study were patients with histologically
confirmed current or former endometrial or invasive
epithelial ovarian cancer disease who were treated at
Erlangen University Hospital. The controls originate
from the three studies mentioned above. Women who
had any other types of cancer were not eligible for in-
clusion in the study. All subjects had to complete the
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same self-reported medical history form and the same
study questionnaire. The age criteria of cases and con-
trols were to be over 40 and less than 85 years. The
ethics committee of the medical faculty at Friedrich
Alexander University, Erlangen, approved the study and
all of the patients and healthy participants provided
written informed consent.
Data acquisition
A standardized questionnaire including modules on
pregnancy history, previous use of hormonal contracep-
tives and hormone replacement therapy, medical history,
family history, and lifestyle was filled out by the patients
and healthy control individuals, and was completed in a
structured interview with trained medical personnel if
any questions had not been fully answered. The question
about a history of endometriosis was expressed in a
“yes/no/don’t know” form, and was answered by cases
and controls in the same way when completing the
questionnaire. Additional information for patients was
obtained from the patient charts, such as information
about medical procedures, histology of the tumor, and
concomitant medication.
Statistical considerations
The primary objective was to investigate whether infor-
mation about endometriosis can be used to assess the
risk for ovarian or endometrial cancer, in addition to
other well-known risk factors. For this purpose, a mul-
tiple logistic regression model was fitted with cancer
case–control status as a binary outcome (yes vs. no) and
the following predictors: endometriosis status (categor-
ical; yes vs. no), age (continuous), BMI (continuous),
number of pregnancies (integer), and oral contraceptive
use (categorical; yes vs. no). The Wald test was per-
formed for endometriosis status. A significant P value
would indicate that endometriosis information is an add-
itional risk factor for ovarian or endometrial cancer. The
regression model was also used to estimate adjusted
odds ratios (ORs), particularly for endometriosis status.
Patients for whom outcome data were lacking and pa-
tients with missing information on age or endometriosis
were excluded. Missing predictor values were imputed
using single “best guesses” (median value of continuous
or integer predictors, the most common value of cat-
egorical or ordinal predictors) based on nonmissing data
across all subjects. Continuous predictors were used as
natural cubic spline functions to describe nonlinear
effects [52]. The number of degrees of freedom (1 or 2)
of each predictor was determined as done recently
in [53].
The performance of the logistic regression model in
terms of discrimination and calibration (“goodness of
fit”) was assessed using the area under the receiver
operating characteristic curve (AUC) and the Hosmer–
Lemeshow statistic applied to the case–control design
[54]. The AUC ranges from 0.5 (no discrimination be-
tween cases and controls) to 1 (perfect discrimination).
It can be interpreted as representing the probability
that the model will give a person who has disease a
higher probability of being diseased than it gives to a
randomly chosen healthy person. In accordance with
Hosmer and Lemeshow, patients were ranked with re-
spect to the predicted conditional probability of ovarian
or endometrial cancer and categorized into equal-sized
groups based on percentiles. Frequencies of predicted
events in each group were compared with frequencies
of observed events in each group using a scatter plot
and the Hosmer–Lemeshow χ2 test. A large P value in-
dicates satisfactory calibration.
Model building was evaluated by 10-fold cross-
validation with 20 repetitions to address overfitting. For
this purpose, the model-building process (i.e., deter-
mination of cubic spline functions and estimation of re-
gression coefficients) was carried out on each training
set, resulting in several logistic regression models (one
model per set), which were then used to calculate the
AUCs on the corresponding validation data sets. The
average of all these AUCs was taken as an evaluation
measure. This cross-validated AUC may be regarded as
an estimation of the expected probability of two ran-
domly chosen future ill or healthy subjects being cor-
rectly classified as ill or healthy, respectively, using the
main regression model described above.
As sensitivity analysis, a simple logistic regression model
was fitted to get an unadjusted OR for endometrioses
status.
All of the tests were two-sided, and a P value of < 0.05
was regarded as statistically significant. Calculations were
carried out using the R system for statistical computing




A total of 1305 participants were included in the ana-
lyses, of whom 165 were patients with ovarian cancer,
131 were patients with endometrial cancer, and 1016
were control individuals. Complete information with all
variables was available for 90 % of the participants. The
proportions of missing predictor values were between
5.5 and 6.5 %. The missing values were imputed, as de-
scribed above. Descriptive statistics are shown in Table 1.
Endometriosis was noted by 2.1 % of the controls (n =
21) and by 4.8 % of the cases (n = 14). The mean age of
subjects with endometriosis was 53.2 years for cases and
57.7 years for controls. Endometriosis was present in 4.2 %
of the ovarian cancer patients (seven of 165 patients) and
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in 5.3 % of the endometrial cancer patients (seven of 131
patients).
Prediction of ovarian or endometrial cancer
The preliminary logistic regression analyses showed
that the continuous predictors of age and BMI fitted
best as cubic spline functions both with two degrees
of freedom. The main logistic regression analyses in-
dicated that endometriosis status is a risk factor for
ovarian or endometrial cancer (P < 0.01, Wald test), in
addition to well-known risk factors. Women with a
history of endometriosis had an increased risk of de-
veloping ovarian or endometrial cancer when all other
predictors were also considered (Table 2).
Oral contraceptive use was protective, but the number
of pregnancies did not appear to influence the risk of
cancer in this study. Both younger women and older
women had a higher risk than medium-aged women.
There were no relevant differences between older and
younger women. Women with a high BMI had a higher
risk than women with a medium or low BMI. There
were no relevant differences between women with a low
and medium BMI (Table 2).
The logistic regression model appeared to be well-
calibrated (P = 0.44, Hosmer–Lemeshow χ2 test). The
AUC on the whole data set was 0.685; the cross-
validated AUC was slightly smaller (0.675), indicating
slight overfitting. Figure 1 shows that there was a good
correlation between the observed frequencies of ovarian
or endometrial cancer cases and the frequencies pre-
dicted by the regression model.
The sensitivity analysis yielded a similar result. The
unadjusted OR for endometriosis status was 2.41 (95 %
CI, 1.21 to 4.81) indicating that the predictors of the mul-
tiple regression model behaved unsuspiciously.
Discussion
In this case–control study, self-reported endometriosis
was confirmed as a risk factor for a combined group of
ovarian or endometrial cancer patients between the age
Table 1 Characteristics of the study participants, showing mean and standard deviation (SD) for continuous characteristics and
frequency and percentage for categorical characteristics
Characteristic Controls (n = 1016) Cases (n = 289) Ovarian cancer cases (n = 165) Endometrial cancer cases (n = 131)a
Mean or n SD or % Mean or n SD or % Mean or n SD or % Mean or n SD or %
Age [years] 60.9 9.3 62.1 11.1 59.5 11.1 65.6 10.5
Body mass index [kg/m2] 25.5 4.3 27 5.8 26 4.7 28.3 6.9
Self-reported endometriosis
No 995 97.9 275 95.2 158 95.8 124 94.7
Yes 21 2.1 14 4.8 7 4.2 7 5.3
Oral contraceptive use
No 275 27.1 141 48.8 72 43.6 71 54.2
Yes 741 72.9 148 51.2 93 56.4 60 45.8
Pregnancies (n)
0 121 11.9 41 14.2 14 8.5 27 20.6
1 165 16.2 62 21.5 31 18.8 32 24.4
2 373 36.7 100 34.6 66 40.0 37 28.2
3 219 21.6 52 18.0 35 21.2 19 14.5
4+ 138 13.6 34 11.8 19 11.5 16 12.2
aSummed up numbers of ovarian and endometrial cancer cases is larger than 289, because there were cases with both ovarian and endometrial cancer
Table 2 Logistic regression analyses, showing adjusteda odds
ratios (ORs), with the corresponding 95 % confidence intervals
(CIs) in brackets
Predictor OR (95 % CI)
Ageb Younger vs. medium 1.36 (1.11, 1.66)
Older vs. medium 1.24 (1.07, 1.43)
Older vs. younger 0.91 (0.70, 1.18)
BMIc Low vs. medium 0.99 (0.83, 1.17)
High vs. medium 1.26 (1.09, 1.46)
High vs. low 1.28 (0.95, 1.72)
Oral contraceptive use Yes vs. no 0.43 (0.32, 0.58)
No. of pregnancies Per-pregnancy increase 0.93 (0.84, 1.02)
Self-reported endometriosis yes vs. no 2.63 (1.28, 5.41)
BMI body mass index
aORs were estimated using a multiple logistic regression model, with the
predictors listed in the first column of the table
bAge was used as a nonlinear continuous predictor. It was evaluated at the
first sextile (“young” — i.e., 51 years), median (“medium” — i.e., 62 years), and
fifth sextile (“older” — i.e., 70 years)
cBMI was used as a nonlinear continuous predictor. It was evaluated at the
first sextile (“low” — i.e., 21.7 kg/m2), median (“medium” — i.e., 25.0 kg/m2),
and fifth sextile (“high” — i.e., 30.1 kg/m2)
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of 40 and 85. In addition, other already well-known risk
factors for ovarian and endometrial cancer such as age
and BMI were confirmed.
Endometriosis has been identified as a risk factor for sub-
types of ovarian cancer [55, 56]. In a large, multicenter
study including more than 1500 patients with endometri-
osis, 7900 patients with ovarian carcinoma and 13,200 con-
trol patients, endometriosis was identified as a risk factor
for clear cell, endometrioid, and low-grade serous ovarian
carcinoma [57]. Clear increases in risk were found in the
group of endometriosis patients for clear cell ovarian car-
cinoma (OR 3.75; 95 % CI, 3.04 to 4.58), for endometrioid
ovarian carcinoma (OR 2.32; 95 % CI, 1.94 to 2.78),
and for low-grade serous ovarian carcinoma (OR 2.02;
95 % CI, 1.38 to 2.97). These findings did not apply
to high-grade serous ovarian carcinoma (OR 1.11; 95 %
CI, 0.96 to 1.29). In a national in-patient registry in
Sweden from 1969 to 1983 a cohort of 64,492 pa-
tients with a hospital diagnosis of endometriosis was
also found to have a significantly elevated risk for ovarian
cancer [58].
Until now, endometriosis has not been defined as a
risk factor for endometrial cancer. There are cur-
rently no data from population-based studies suggesting
an association between endometriosis and endometrial
cancer. A retrospective case–control study including 1399
patients did not show any association between endo-
metrial cancer and endometriosis [59]. Previously re-
ported data on endometriosis as a risk factor for
endometrial cancer are inconclusive [37–42]. The stud-
ies mentioned have limited case numbers in comparison
with the present study, which confirmed an increased
risk.
As mentioned above, an increased risk of epithelial ovar-
ian cancer in patients with endometriosis has been shown
in numerous epidemiologic studies, but the pathogenesis
is poorly understood [35]. Current molecular studies have
sought to link the two conditions via pathways related to
oxidative stress, inflammation, and hyperestrogenism. As
a result of repetitive hemorrhage, with an accumulation of
heme and free iron in endometriotic lesions, reactive oxy-
gen species are produced and play a role in the develop-
ment of ovarian carcinoma [60]. Similarly, cytokines and
mediators are responsible for the microenvironment of
endometriosis and endometriosis-associated ovarian
carcinoma.
Although endometriosis is not yet established as a risk
factor for endometrial cancer, recent studies have dis-
cussed an influence of the epithelial-to-mesenchymal
transition and stem cells in endometrial cancer [61].
Fig. 1 Observed and predicted frequencies of ovarian or endometrial cancer cases. The patients were ranked according to the predicted
conditional probability of being a case by the logistic regression model, and grouped into 10 categories based on deciles. Numbers of observed
cancer cases in each category (“observed events”) are plotted against the summed-up predicted probabilities of being a case in each category
(“predicted events”). Points below the gray line indicate when the regression model overestimates the cancer risk, and points above it indicate
underestimation. A perfect prediction model would have all points on the gray line
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Endometrial stem cells are frequent in endometrial tis-
sue during menstruation. It may therefore be speculated
that endometrial stem cells may play an important role
in the development of endometriotic implants [62] and
thus in endometriosis and endometrial cancer.
A molecular pathway cable of confirming the hypoth-
esis is not currently known. An epigenetic analysis has
identified HNF1B as a subtype-specific susceptibility
gene for ovarian cancer [16]. Different variants in
HNF1B are associated with the risk of serous or clear
cell epithelial cancer. HNF1B is also overexpressed in
endometriosis [16], supporting the hypothesis that the
gene may have an oncogenic role in initiating specific
subtypes of ovarian cancer in patients with endometri-
osis. HNF1B might also be the link to endometrial can-
cer. A genome-wide association study has linked minor
alleles of certain single nucleotide polymorphisms in
HNF1B with a decreased risk of endometrial cancer
[23]. Further research is needed in order to define a
molecular pathway.
It has been hypothesized that endometriosis develops
from stem/progenitor cells. It would be of great interest
to associate the technique for identifying stem/progeni-
tor cells in endometriotic tissues with an analysis of gen-
etic/epigenetic changes in these cells that may possibly
affect their molecular signature and activity [63]. This
might make it possible to identify a molecular pathway
for the development of ovarian or endometrial cancer in
patients with endometriosis.
This study is the first case–control study to confirm
the influence of endometriosis on ovarian and endomet-
rial cancer in a population in Germany. One advantage
of this case–control study was the validated epidemio-
logical questionnaire that was used. A limitation is the
small number of cases, due to the low incidences of
ovarian and endometrial cancer, at 18.6 patients per
100,000 population and 26.9 patients per 100,000 popu-
lation, respectively. Similarly in this study there are
fewer patients with reported endometriosis than ex-
pected by a prevalence of 10 % in reproductive age. This
effect can be caused by a notoriously underdiagnosed
disease and the prespecified age range from 40 to 85 in
our cases and controls with a consecutively decrease in
symptoms [64], which leads probably to a reduced de-
scription in the medical history form and the study
questionnaire. The number of 2.1 % endometriosis in
controls respectively 4.8 % in cases is congruent with the
data of the Iowa Women’s Health Study with a cohort of
more than 40,000 postmenopausal women, which publi-
cated a number of 3.8 % of self-reported history of endo-
metriosis [40]. Self-reported endometriosis is an inexact
and inaccurate method of assessment and may force up
the case numbers for endometriosis. Also the higher
number of self-reported endometriosis in patients with
ovarian- or endometrial-cancer could originate in a bet-
ter knowledge and remembering of their previous
gynecological diseases. Further limitations are the retro-
spective analysis of the data and the combined analysis
of ovarian and endometrial cancer cases. The reason for
the combined analysis was the low rate of seven patients
with endometriosis in each group of patients with ovar-
ian (n = 158) or endometrial cancer (n = 124). Statistical
analyses were performed for each group, and there was a
significantly higher risk in the group of patients with
endometrial cancer and no significance in the patients
with ovarian cancer. However, these data are not shown,
due to the small number of cases of endometriosis in
each group. Our results do not necessarily hold for sub-
jects younger than 40, because women of this age were
excluded from this study.
Conclusions
There have been few studies addressing the question of
whether endometriosis is a risk factor for ovarian or
endometrial cancer, and incorporating this into a clinical
prediction model would require precise characterization
of endometriosis as a risk factor. Larger studies are
needed in order to confirm the data for subgroups - espe-
cially for a younger population than the described one -,
to examine molecular pathways, and to understand the
pathogenesis.
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